Q-omics provides the consensus-scored TTC30B profile across patient tissues and cancer cell-line models. TTC30B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTC30B is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TTC30B RNA expression shows 20,702 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where TTC30B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC30B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC30B survival associations across molecular data types. TTC30B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC30B RNA expression–survival associations across cancer types. High TTC30B expression shows unfavorable associations in KICH, KIRP, LGG and UVM, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTC30B RNA expression.
This table summarizes TTC30B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTC30B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC30B shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, LIHC, HNSC and BRCA. The THCA box plot shows higher TTC30B RNA expression in normal versus tumor tissue (log2 FC = −1.609, t-test p < 0.001).
This table shows molecular features associated with TTC30B in patient tissues and cancer cell lines. In patient samples, TTC30B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC30B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
